HER2CLIMB Resistance Mechanisms

Possible molecular and clinical mechanisms that may drive progression on the tucatinib, trastuzumab, and capecitabine regimen

The HER2CLIMB regimen combines tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. When disease progresses despite this regimen, it may reflect acquired resistance, aggressive disease biology, pharmacokinetic factors, or a mixture of these.

Why resistance may happen

Cancer progression on this regimen does not always mean the same thing biologically.

In some cases, the tumour finds a way around HER2 blockade. In others, the main issue may be disease burden, sanctuary-site progression, or drug-exposure variability rather than a single new mutation.

Potential resistance mechanisms

EGFR amplification or overexpression

EGFR upregulation may allow HER2-independent signalling even when tucatinib is blocking HER2.

Activation of downstream effectors

Alterations such as PIK3CA mutations, PTEN loss, or RAS/RAF pathway activation can keep growth and survival signalling active despite HER2 blockade.

HER2 truncations

Truncated HER2 forms such as p95HER2 can remove the extracellular region needed for trastuzumab binding while leaving kinase signalling active.

Cell-cycle dysregulation

Changes such as RB1 loss or cyclin E amplification may allow continued cell division even when upstream HER2 signalling is partly controlled.

Alternative receptor tyrosine kinase upregulation

Tumours may compensate through pathways such as:

MET
FGFR
IGF1R

These can provide bypass signalling when HER2 is inhibited.

Phenotypic transformation

Some tumours may shift toward a more aggressive or less HER2-dependent state, including a more basal-like phenotype.

Where the evidence is strongest

Current evidence comes mainly from:

preclinical tucatinib-resistance models
molecular analyses of patient samples
broader HER2-targeted-resistance literature

The most commonly discussed mechanisms include:

EGFR amplification
PIK3CA mutations
PTEN loss
RAS/RAF alterations
HER2 truncations
RB1 loss
cyclin E amplification
MET, FGFR, and IGF1R upregulation
phenotypic shift or loss of HER2 dependence

Other practical reasons progression may look rapid

Not all rapid progression is explained by a single molecular resistance mechanism.

Other contributors may include:

high tumour burden
aggressive visceral disease
active CNS disease
pharmacokinetic variability
reduced effective drug exposure

How this information may help

This information may help support discussions about:

repeat biopsy or liquid biopsy
switching to another HER2-targeted therapy
adding pathway-directed treatment
clinical-trial eligibility
whether the pattern of progression suggests bypass signalling or phenotype change

Questions to discuss with the care team

whether tissue or liquid-biopsy testing is appropriate
whether any actionable alterations may change treatment options
whether the current progression pattern suggests a known resistance route
whether clinical trials or alternative HER2-targeted strategies are available

References

Abstract PD8-06: Acquired resistance to tucatinib
https://aacrjournals.org/cancerres/article/82/4_Supplement/PD8-06/681486/Abstract-PD8-06-Acquired-resistance-to-tucatinib

Treating advanced breast cancer: a spotlight on tucatinib
https://www.dovepress.com/treating-advanced-unresectable-or-metastatic-her2-positive-breast-canc-peer-reviewed-fulltext-article-BCTT

Potential Resistance Mechanism to Tucatinib in HER2+ Breast Cancer
https://conference-correspondent.com/highlights/sabcs/potential-resistance-mechanism-to-tucatinib-in-her2-breast-cancer

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.